Does ischemic preconditioning increase flap survival by ADORA2B receptor activation?
| Autor: | Kerim Ünal, Mutay Aslan, Matteo Amoroso, Özlenen Özkan, Mehmet Can Ubur, Ömer Özkan, Pinar Ulker, Ibrahim Bassorgun, Filiz Ozcan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Agonist
medicine.medical_specialty Adenosine Physiology medicine.drug_class Ischemia 030204 cardiovascular system & hematology Pharmacology Receptor Adenosine A2B Surgical Flaps 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Physiology (medical) Internal medicine parasitic diseases medicine Animals Humans cardiovascular diseases Rats Wistar Ischemic Preconditioning Receptor Tissue Survival Hematology business.industry Antagonist medicine.disease Rats Reperfusion Injury Ischemic preconditioning Female Cardiology and Cardiovascular Medicine business Adenosine A2B receptor medicine.drug |
| Zdroj: | Clinical Hemorheology and Microcirculation. 75:151-162 |
| ISSN: | 1875-8622 1386-0291 |
| Popis: | BACKGROUND Ischemic preconditioning (IPC) is defined as raising tolerance to subsequent ischemic stress by exposing tissues to sub-lethal ischemia. Although many candidates have been suggested, recent studies have clearly demonstrated that adenosine-mediated ADORA2B receptor (ADORA2BR) activation is the main mechanism involved in IPC. While the tissue-protective role of this mechanism has been demonstrated in different ischemia/reperfusion (I/R) models, its role in flap surgery-derived I/R damage has not to date been investigated. OBJECTIVE To investigate the role of adenosine and ADORA2BR activation in IPC-mediated tissue protection in an epigastric flap model. METHODS Animals were divided into five main groups, all of which were then divided into two subgroups depending on whether or not they were exposed to IPC before the I/R procedure, which consisted of 6 hours of ischemia and 6 days of reperfusion. No drugs were administered in Group 1 (the control group). Animals in Group 2 were pretreated with CD73-inhibitor before IPC application or the ischemic period. Animals in Group 3 were pretreated with adenosine. Animals in Group 4 were pretreated with an ADORA2BR antagonist, and those in Group 5 with an ADORA2BR agonist. After 6 days of reperfusion, tissue survival was evaluated via histological and macroscopic analysis. RESULTS IPC application significantly enhanced CD73 expressions and adenosine concentrations (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|